ATHIRA PHARMA INC. - COMMON STOCK

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022

03 Aug 2022 11:28:00 By Nasdaq GlobeNewswire

Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022

02 Aug 2022 15:30:00 By Nasdaq GlobeNewswire

Athira Pharma to Present Clinical and Preclinical Data at Alzheimer’s Association International Conference 2022

25 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

22 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology Research

07 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting

19 May 2022 12:06:13 By Nasdaq GlobeNewswire

Athira Issues Statement in Response to Richard A. Kayne’s Suspension of His Proxy Contest

16 May 2022 16:49:31 By Nasdaq GlobeNewswire

Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting

16 May 2022 07:00:01 By Nasdaq GlobeNewswire

Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates

12 May 2022 16:05:02 By Nasdaq GlobeNewswire

Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting

11 May 2022 16:15:00 By Nasdaq GlobeNewswire

Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease

09 May 2022 07:00:02 By Nasdaq GlobeNewswire

Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote “FOR” All of Athira’s Highly Qualified Director Nominees

05 May 2022 12:03:56 By Nasdaq GlobeNewswire

Athira Mails Letter to Shareholders Emphasizing the Company’s Strong Position and Qualified Board as it Enters Pivotal Chapter

05 May 2022 08:00:03 By Nasdaq GlobeNewswire

Leading Independent Proxy Advisory Firm ISS Recommends that Athira Shareholders Vote on Athira’s WHITE Proxy Card

04 May 2022 18:46:09 By Nasdaq GlobeNewswire

Athira Files Investor Presentation Highlighting Successful Execution of its Strategy and Highly Qualified Board and Leadership

26 Apr 2022 08:00:03 By Nasdaq GlobeNewswire

Athira Mails Letter to Shareholders Highlighting the Strength of its Board and Record of Deliberate Board Refreshment

20 Apr 2022 09:02:06 By Nasdaq GlobeNewswire

Athira Files Definitive Proxy Statement and Mails Letter to Shareholders

05 Apr 2022 16:04:20 By Nasdaq GlobeNewswire

Athira Pharma Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions

04 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Athira Pharma Highlights Strong Execution of Strategy and Positioning for the Future

30 Mar 2022 12:12:04 By Nasdaq GlobeNewswire

Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update

24 Mar 2022 16:05:01 By Nasdaq GlobeNewswire